United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregn

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - sunitinib malate 16,71 mg - eq. sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib malate 16.71 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - sunitinib malate 33,41 mg - eq. sunitinib 25 mg - capsule, hard - 25 mg - sunitinib malate 33.41 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - sunitinib malate 66,83 mg - eq. sunitinib 50 mg - capsule, hard - 50 mg - sunitinib malate 66.83 mg - sunitinib

United States - English - NLM (National Library of Medicine)

northstar rxllc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregna

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 37,5 mg - capsule, hard - 37,5 mg - sunitinib 37.5 mg - sunitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sunitinib 50 mg - capsule, hard - 50 mg - sunitinib 50 mg - sunitinib

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - sunitinib - capsules - sunitinib 12.5 mg - sunitinib - sunitinib s.k. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib s.k. is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.